SCYNEXIS Entered Into Binding MoU For Amendment To License Agreement Between Co And GSK; Granted GSK Royalty-Bearing, License For Development, Manufacture, And Commercialization Of Ibrexafungerp, Including The Approved Product BREXAFEMME

Author: Benzinga Newsdesk | January 02, 2024 05:13pm
-SEC Filing Granted for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). The terms of the License Agreement are further

-SEC Filing

 

Granted for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). The terms of the License Agreement are further described in SCYNEXIS's Form 8-K dated March 30, 2023.

Posted In: GSK SCYX